Mode of Action of MetrioPharm's Lead Molecule MP1032

Video Presentation by Dr. Brysch

News

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts - 2024-Mar-13

MetrioPharm AG today announced that it has established a Scientific Advisory Board (SAB). The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy.

» more

Investor Relations

MetrioPharm Investor Relations News QIII 2024 - 2024-Sep-26

Mode of Action of MetrioPharm's Lead Molecule MP1032, MetrioPharm AG Company Calendar 2024, MetrioPharm AG informs

» more

Navigation

Home
About us
Technology
Pipeline
Investors
Press
Contact

Social

  

Newsletter

Subscribe to our press releases with the
MetrioPharm PR newsletter

Investors can subscribe to our quaterly corporate information with the
MetrioPharm IR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Phone: +41 44 552 7190

Germany (R&D)

MetrioPharm Deutschland GmbH

Am Borsigturm 100
13507 Berlin

Phone: +49 30 3384 395 02

Imprint
Privacy policy (We don’t collect cookies)
Sitemap